Literature DB >> 24727385

Signaling pathways involved in MDSC regulation.

Prashant Trikha1, William E Carson2.   

Abstract

The immune system has evolved mechanisms to protect the host from the deleterious effects of inflammation. The generation of immune suppressive cells like myeloid derived suppressor cells (MDSCs) that can counteract T cell responses represents one such strategy. There is an accumulation of immature myeloid cells or MDSCs in bone marrow (BM) and lymphoid organs under pathological conditions such as cancer. MDSCs represent a population of heterogeneous myeloid cells comprising of macrophages, granulocytes and dendritic cells that are at early stages of development. Although, the precise signaling pathways and molecular mechanisms that lead to MDSC generation and expansion in cancer remains to be elucidated. It is widely believed that perturbation of signaling pathways involved during normal hematopoietic and myeloid development under pathological conditions such as tumorogenesis contributes to the development of suppressive myeloid cells. In this review we discuss the role played by key signaling pathways such as PI3K, Ras, Jak/Stat and TGFb during myeloid development and how their deregulation under pathological conditions can lead to the generation of suppressive myeloid cells or MDSCs. Targeting these pathways should help in elucidating mechanisms that lead to the expansion of MDSCs in cancer and point to methods for eliminating these cells from the tumor microenvironment.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Jak/Stat; Myeloid derived suppressor cells (MDSC); PI3K; Ras; TGFβ; Tumor microenvironment

Mesh:

Substances:

Year:  2014        PMID: 24727385      PMCID: PMC4140957          DOI: 10.1016/j.bbcan.2014.04.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  156 in total

1.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

2.  Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors:  Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

3.  Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.

Authors:  Athanasios Kotsakis; Malgorzata Harasymczuk; Bastian Schilling; Vasilis Georgoulias; Athanassios Argiris; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2012-04-13       Impact factor: 2.303

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

7.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

8.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Authors:  Maciej Kujawski; Marcin Kortylewski; Heehyoung Lee; Andreas Herrmann; Heidi Kay; Hua Yu
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

9.  Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.

Authors:  Minu K Srivastava; Jacobus J Bosch; James A Thompson; Bruce R Ksander; Martin J Edelman; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Immunother       Date:  2008-03-06       Impact factor: 6.968

10.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

View more
  87 in total

Review 1.  Myeloid Cells and Chronic Liver Disease: a Comprehensive Review.

Authors:  Min Lian; Carlo Selmi; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

2.  Opposite Effects of Coinjection and Distant Injection of Mesenchymal Stem Cells on Breast Tumor Cell Growth.

Authors:  Huilin Zheng; Weibin Zou; Jiaying Shen; Liang Xu; Shu Wang; Yang-Xin Fu; Weimin Fan
Journal:  Stem Cells Transl Med       Date:  2016-06-28       Impact factor: 6.940

3.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 4.  Phenotype, development, and biological function of myeloid-derived suppressor cells.

Authors:  Yang Zhao; Tingting Wu; Steven Shao; Bingyi Shi; Yong Zhao
Journal:  Oncoimmunology       Date:  2015-10-14       Impact factor: 8.110

5.  Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences.

Authors:  Yaping Xu; Wenxiu Zhao; Duan Wu; Jianfeng Xu; Suqiong Lin; Kai Tang; Zhenyu Yin; Xiaomin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity.

Authors:  Yi Ban; Junhua Mai; Xin Li; Marisa Mitchell-Flack; Tuo Zhang; Lixing Zhang; Lotfi Chouchane; Mauro Ferrari; Haifa Shen; Xiaojing Ma
Journal:  Cancer Res       Date:  2017-04-17       Impact factor: 12.701

7.  Arctigenin Ameliorates Inflammation by Regulating Accumulation and Functional Activity of MDSCs in Endotoxin Shock.

Authors:  Hui Shi; Guanjun Dong; Fenglian Yan; Hui Zhang; Chunxia Li; Qun Ma; Junfeng Zhang; Zhaochen Ning; Zhihua Li; Jun Dai; Jiankuo Ming; Runping Fang; Chuanping Si; Huabao Xiong
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

8.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

9.  TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy.

Authors:  Padmini Jayaraman; Falguni Parikh; Jared M Newton; Aurelie Hanoteau; Charlotte Rivas; Rosemarie Krupar; Kimal Rajapakshe; Ravi Pathak; Kavin Kanthaswamy; Cassie MacLaren; Shixia Huang; Cristian Coarfa; Chad Spanos; Dean P Edwards; Robin Parihar; Andrew G Sikora
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

10.  The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.

Authors:  Y Takeda; T Kato; H Ito; Y Kurota; A Yamagishi; T Sakurai; A Araki; H Nara; N Tsuchiya; H Asao
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.